Outlook Therapeutics (OTLK) Cash & Equivalents (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Cash & Equivalents data on file, last reported at $7.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.7 million, up 2.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.7 million (up 2.54% YoY), and the FY2025 annual result was $8.1 million, down 45.85% from the prior year.
• Cash & Equivalents slipped to $7.7 million in Q1 2026 per OTLK's latest filing, from $8.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $58.4 million in Q1 2022 and troughed at $5.7 million in Q4 2024.
• A 5-year average of $23.9 million and a median of $17.4 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents jumped 57.19% in 2022, then sank 84.0% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $52.3 million in 2022, then slumped by 80.21% to $10.4 million in 2023, then tumbled by 44.94% to $5.7 million in 2024, then surged by 52.17% to $8.7 million in 2025, then decreased by 10.71% to $7.7 million in 2026.
• Business Quant data shows OTLK's Cash & Equivalents at $7.7 million in Q1 2026, $8.7 million in Q4 2025, and $8.1 million in Q3 2025.